NCT01287923 (BMS-LyTrans) is a clinical trial in DLBCL, sponsored by Rennes University Hospital.

Who is sponsoring NCT01287923?

NCT01287923 is sponsored by Rennes University Hospital.

Is NCT01287923 still recruiting?

NCT01287923 is currently completed. Last updated 10 April 2018.

Last reviewed 2018-04-10 · How we verify

NCT01287923: BMS-LyTrans

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans

Completed Last updated 10 April 2018

What this trial tests

trial in DLBCL in 326 participants. Completed in 1 September 2017.

Timeline

21 February 2011

Primary endpoint
8 June 2017

1 September 2017

Quick facts

Lead sponsor	Rennes University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	326
Start date	21 February 2011
Primary completion	8 June 2017
Estimated completion	1 September 2017
Sites	17 locations across France

Conditions studied

DLBCL — all drugs for DLBCL →

Sponsor

Rennes University Hospital

Who can join

Adults 18 to 70, any sex, with DLBCL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent high grade lymphoma in adults. Although immunotherapy has improved its prognosis, DLBCL is a heterogeneous disease with patients exhibiting a wide range of outcomes with a 5-year overall survival ranging between 55 to 94% depending of the International Prognostic Index factor. Diagnostic and prognostic biomarkers are mandatory to optimize treatment. Transcriptomics has been used to detect such new biomarkers using microarrays analyses applied to RNA collected from total tumor tissues or cell extracts. Molecular prognostic factors have been thoroughly studied in DLBCL tumor tissues. However, it is a big challenge to obtain transcriptomic-qualified tumor samples in a multicentric and prospective clinical trial. Coordinating nvestigator hypothesized that blood may be a deep source of native and secreted analytes and therefore carries transcriptomic signatures related to DLBCL and its prognosis. This project is organized in the extension of the GOELAMS-075 clinical trial which concerns aggressive DLBCL.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.
Rossille D, Azzaoui I, Feldman AL, Maurer MJ, et al · · 2017 · cited 39× · PMID 28035137 · DOI 10.1038/leu.2016.385
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.
Le Gallou S, Lhomme F, Irish JM, Mingam A, et al · · 2021 · cited 17× · PMID 34975843 · DOI 10.3389/fimmu.2021.755623
Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.
Fan L, Li L, Zhou Y, Li J. · · 2017 · cited 6× · PMID 32300390 · DOI 10.14740/jh320w

Verify or expand the search:

Other recruiting trials for DLBCL

Currently open trials in the same condition.

NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT06758037 — Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy · Phase 2 · recruiting
NCT06779435 — A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL · recruiting
NCT06701357 — CR-CHOP+X in Previously Untreated DEL · Phase 2 · recruiting
NCT07335120 — A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma · recruiting

Other Rennes University Hospital trials

Trials by the same sponsor.

NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01287923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
Last refreshed: 10 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01287923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing